YaoPharma’s new API Tenofovir Disoproxil Fumarate received CFDA approval
22 / 02 / 2017
On Feb. 21, 2017, YaoPharma received the registration certificate of “Tenofovir Disoproxil Fumarate” from CFDA.
Tenofovir Disoproxil Fumarate is a phosphodiester analogue of the aliphatic nucleoside adenosine monophosphate, which inhibits the activity of the human immunodeficiency virus -1 (HIV-1) reverse transcriptase and hepatitis B virus DNA polymerase.
YaoPharma developed this product with a new synthetic route, successfully realized the localization of the drug, providing an important guarantee for the accessibility and affordability of patients.
About YAOPHARMA
YaoPharma is a pharmaceutical manufacturer integrating R&D, manufacturing and marketing & sales functions, with multiple subsidiaries, and fully complying with Chinese GMP. Its oral solid line passed GMP inspection from Health Canada and US FDA; its API site passed GMP inspection from US FDA, EU EDQM, Australia TGA and Japan PMDA, etclearn more...
